MX9706588A - Metodo para estimular una respuesta inmune. - Google Patents
Metodo para estimular una respuesta inmune.Info
- Publication number
- MX9706588A MX9706588A MX9706588A MX9706588A MX9706588A MX 9706588 A MX9706588 A MX 9706588A MX 9706588 A MX9706588 A MX 9706588A MX 9706588 A MX9706588 A MX 9706588A MX 9706588 A MX9706588 A MX 9706588A
- Authority
- MX
- Mexico
- Prior art keywords
- immune response
- stimulating
- individuals
- pathogenic
- ligand
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Electrotherapy Devices (AREA)
- Oscillators With Electromechanical Resonators (AREA)
Abstract
Se describe un método para estimular una respuesta inmune que comprende administrar una cantidad efectiva de una proteína de union CD40. El método es util para tratar individuos infectados con organismos patogénicos u oportunistas e individuos que tienen una respuesta inmune deprimida. Las proteínas de union CD40 incluyen ligando CD40, anticuerpos monoclonales que se unen específicamente a CD40 y combinaciones de los mismos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39623095A | 1995-03-01 | 1995-03-01 | |
PCT/US1996/002839 WO1996026735A1 (en) | 1995-03-01 | 1996-02-29 | Method for stimulating an immune response |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9706588A true MX9706588A (es) | 1997-11-29 |
Family
ID=23566398
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9706588A MX9706588A (es) | 1995-03-01 | 1996-02-29 | Metodo para estimular una respuesta inmune. |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP0812206B1 (es) |
JP (1) | JP3657271B2 (es) |
KR (1) | KR19980702490A (es) |
AT (1) | ATE220331T1 (es) |
AU (1) | AU699291B2 (es) |
CA (1) | CA2213798C (es) |
DE (1) | DE69622259T2 (es) |
DK (1) | DK0812206T3 (es) |
ES (1) | ES2179187T3 (es) |
FI (1) | FI973484A (es) |
MX (1) | MX9706588A (es) |
NO (1) | NO973875L (es) |
NZ (1) | NZ305083A (es) |
PT (1) | PT812206E (es) |
WO (1) | WO1996026735A1 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1033406A4 (en) * | 1997-10-27 | 2005-03-09 | Sumitomo Electric Industries | INDUCER FOR THE PRODUCTION OF ANTIGEN-SPECIFIC ANTIBODY, EXPRESSION VECTOR CONTAINING THE GENE REQUIRED THEREFOR, AND METHOD FOR INDUCING THE PRODUCTION OF THE ANTIGEN-SPECIFIC ANTIBODY |
CA2313805A1 (en) * | 1997-12-19 | 1999-07-01 | Immunex Corporation | Method for reducing susceptibility to hiv infection |
CN1762492A (zh) * | 1998-05-23 | 2006-04-26 | 莱顿大学医学中心 | Cd40结合分子和ctl肽在用于***的药物组合物中的用途 |
EP1255560B1 (en) | 2000-02-02 | 2008-10-29 | UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE | Cd40 ligand adjuvant for respiratory syncytial virus vaccine |
PL2066339T3 (pl) | 2006-09-18 | 2015-02-27 | Univ Arkansas | Kompozycje i sposoby zwiększania odpowiedzi immunologicznych |
JP2011502165A (ja) | 2007-10-30 | 2011-01-20 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー | 鞭毛細菌に対する免疫応答を強化する組成物および方法 |
CA3156538C (en) | 2007-11-01 | 2023-12-12 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to eimeria |
MX341775B (es) | 2010-01-21 | 2016-09-02 | The Texas A&M Univ System * | Vectores para vacunas y metodos para potenciar respuestas inmunes. |
AU2011264772B2 (en) | 2010-06-09 | 2015-07-16 | The Board Of Trustees Of The University Of Arkansas | Vaccine and methods to reduce Campylobacter infection |
MX339239B (es) | 2011-04-29 | 2016-05-18 | Apexigen Inc | Anticuerpos anti-cd40 y metodos de uso. |
CN104918957B (zh) | 2012-10-30 | 2018-11-16 | 埃派斯进有限公司 | 抗-cd40抗体及其使用方法 |
ES2968398T3 (es) | 2013-02-14 | 2024-05-09 | Univ Arkansas | Composiciones y métodos para potenciar las respuestas inmunitarias a Eimeria o limitar la infección por Eimeria |
EP3578190A1 (en) | 2013-03-15 | 2019-12-11 | The Board of Trustees of the University of Arkansas | Compositions and methods of enhancing immune responses to enteric pathogens |
CA2986705A1 (en) | 2015-07-16 | 2017-01-19 | Biokine Therapeutics Ltd. | A cxcr4 inhibitor and a pdi antagonist for use in treating cancer |
JP7038064B2 (ja) | 2016-04-18 | 2022-03-17 | セルデックス セラピューティクス インコーポレイテッド | ヒトcd40に結合するアゴニスト抗体およびその使用 |
SG11201809686SA (en) | 2016-05-03 | 2018-11-29 | Univ Arkansas | Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU661360B2 (en) * | 1991-10-25 | 1995-07-20 | Immunex Corporation | Novel cytokine |
AU5098493A (en) * | 1992-08-21 | 1994-03-15 | Schering Corporation | Cd40 ligand, anti cd40 antibodies, and soluble cd40 |
ATE255906T1 (de) * | 1993-10-01 | 2003-12-15 | Immunex Corp | Antikörper gegen cd40 |
-
1996
- 1996-02-29 CA CA002213798A patent/CA2213798C/en not_active Expired - Fee Related
- 1996-02-29 DE DE69622259T patent/DE69622259T2/de not_active Expired - Lifetime
- 1996-02-29 AU AU53011/96A patent/AU699291B2/en not_active Ceased
- 1996-02-29 EP EP96909555A patent/EP0812206B1/en not_active Expired - Lifetime
- 1996-02-29 WO PCT/US1996/002839 patent/WO1996026735A1/en active IP Right Grant
- 1996-02-29 PT PT96909555T patent/PT812206E/pt unknown
- 1996-02-29 DK DK96909555T patent/DK0812206T3/da active
- 1996-02-29 AT AT96909555T patent/ATE220331T1/de not_active IP Right Cessation
- 1996-02-29 NZ NZ305083A patent/NZ305083A/xx not_active IP Right Cessation
- 1996-02-29 JP JP52643096A patent/JP3657271B2/ja not_active Expired - Fee Related
- 1996-02-29 ES ES96909555T patent/ES2179187T3/es not_active Expired - Lifetime
- 1996-02-29 MX MX9706588A patent/MX9706588A/es not_active IP Right Cessation
- 1996-02-29 KR KR1019970705890A patent/KR19980702490A/ko not_active Application Discontinuation
-
1997
- 1997-08-22 NO NO973875A patent/NO973875L/no unknown
- 1997-08-25 FI FI973484A patent/FI973484A/fi unknown
Also Published As
Publication number | Publication date |
---|---|
EP0812206A1 (en) | 1997-12-17 |
DE69622259D1 (de) | 2002-08-14 |
NO973875L (no) | 1997-10-31 |
WO1996026735A1 (en) | 1996-09-06 |
JPH11506418A (ja) | 1999-06-08 |
FI973484A0 (fi) | 1997-08-25 |
PT812206E (pt) | 2002-11-29 |
ATE220331T1 (de) | 2002-07-15 |
KR19980702490A (ko) | 1998-07-15 |
NZ305083A (en) | 1999-06-29 |
EP0812206B1 (en) | 2002-07-10 |
FI973484A (fi) | 1997-10-24 |
AU5301196A (en) | 1996-09-18 |
CA2213798C (en) | 2001-02-06 |
DK0812206T3 (da) | 2002-09-09 |
JP3657271B2 (ja) | 2005-06-08 |
DE69622259T2 (de) | 2003-03-27 |
NO973875D0 (no) | 1997-08-22 |
CA2213798A1 (en) | 1996-09-06 |
ES2179187T3 (es) | 2003-01-16 |
AU699291B2 (en) | 1998-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9706588A (es) | Metodo para estimular una respuesta inmune. | |
EP0724456A4 (en) | ANTIBODIES AGAINST CD40 | |
DE69316948T2 (de) | Lösliche Liganden für CD40 | |
GB9206422D0 (en) | Antibody preparation | |
AU1868695A (en) | Immuno-stimulatory monoclonal antibodies | |
AU2821195A (en) | Cross-reacting monoclonal antibodies specific for e-selectin and p-selectin | |
CA2429027A1 (en) | Antibodies against human receptor h4-1bb | |
ZA946767B (en) | Monocional antibodies having property of causing apoptosis. | |
ATE309371T1 (de) | Protein mit dnase-aktivität |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
MM | Annulment or lapse due to non-payment of fees |